A Practical FDA-Aligned Guide To SBOM Management For Medical Device Cybersecurity

As medical devices become increasingly software-driven, connected, and interoperable, cybersecurity has evolved from an IT concern into a critical patient safety issue. Modern medical devices now rely heavily on third-party software components, open-source libraries, cloud connectivity, wireless communication, and complex digital ecosystems that introduce significant cybersecurity risks throughout the product lifecycle.

In response to the growing threat landscape, global regulators particularly the U.S. Food and Drug Administration (FDA) now expect medical device manufacturers to establish robust cybersecurity governance programs supported by comprehensive Software Bill of Materials (SBOM) management.

However, many organizations still treat the SBOM as a static regulatory submission document created solely to satisfy premarket requirements. The FDA’s expectations go far beyond document generation.

Under modern FDA cybersecurity guidance, the SBOM is intended to function as a living cybersecurity asset that supports:

• Continuous vulnerability monitoring
• Post-market cybersecurity surveillance
• Threat intelligence integration
• Patch management
• Risk mitigation decision-making
• Secure software lifecycle governance
• Regulatory defensibility

For manufacturers developing software-enabled medical devices, effective SBOM management is rapidly becoming a core component of regulatory compliance, product security, and patient safety assurance.

At Maven Regulatory Solutions, we help medical device manufacturers build practical, FDA-aligned SBOM governance frameworks that integrate cybersecurity risk management into both pre-market and post-market operations.

Understanding FDA Expectations for SBOM Management

The FDA’s cybersecurity framework clearly establishes that SBOMs are not optional administrative artifacts.

Instead, they intend to support ongoing cybersecurity risk management throughout the medical device lifecycle.

FDA Cybersecurity Expectations Include

• Identification of software components and dependencies
• Traceability of third-party and open-source software
• Continuous vulnerability identification
• Demonstration of cybersecurity risk management
• Post-market cybersecurity monitoring
• Secure update and patch management processes
• Documentation of mitigation strategies
• Alignment between cybersecurity controls and patient safety

In practical terms, regulators expect manufacturers to actively use their SBOMs not merely submit them.

Why SBOMs Matter in Medical Device Cybersecurity

Medical devices increasingly rely on software ecosystems that may contain hundreds or even thousands of software components.

Each component can introduce:

• Vulnerabilities
• Unsupported software risks
• Supply chain threats
• Exploitable dependencies
• Hidden cybersecurity exposures

Without a well-maintained SBOM, organizations may struggle to:

• Identify affected products during vulnerability disclosures
• Assess patient safety impact quickly
• Implement timely remediation actions
• Demonstrate regulatory due diligence
• Respond effectively during cybersecurity incidents

A mature SBOM program significantly improves cybersecurity visibility and operational resilience.

Step-By-Step Guide to Effective SBOM Management

Step 1: Align Your SBOM With FDA Cybersecurity Guidance

Before operationalizing an SBOM, manufacturers should ensure it aligns with FDA regulatory intent.

Key FDA Expectations Include

• Accurate software component traceability
• Identification of known vulnerabilities
• Clear dependency visibility
• Integration with risk management systems
• Ongoing cybersecurity monitoring capabilities

Your SBOM should connect directly with:

• Risk management files
• Secure Product Development Lifecycle (SPDL)
• Cybersecurity documentation
• Post-market surveillance systems
• CAPA processes
• Vulnerability management workflows

Organizations treating SBOMs as isolated compliance documents often fail to meet broader FDA cybersecurity expectations.

Step 2: Validate SBOM Completeness and Accuracy

An incomplete or inaccurate SBOM creates false confidence and increases regulatory risk.

A robust SBOM should contain comprehensive and standardized information.

Best Practice Recommendations

Manufacturers should use automated validation tools to:

• Detect missing fields
• Identify formatting inconsistencies
• Standardizing naming conventions
• Validate dependency mapping
• Improve software traceability

Accurate SBOM data is essential for reliable vulnerability monitoring.

Step 3: Map SBOM Components to Vulnerability Databases

Once validated, SBOM components should be continuously monitored against trusted vulnerability intelligence sources.

Common Vulnerability Sources Include

• National Vulnerability Database (NVD)
• CISA Known Exploited Vulnerabilities (KEV)
• Vendor security advisories
• Industry threat intelligence feeds
• Open-source vulnerability databases
• Security researcher disclosures

Important Considerations

Manufacturers should:

• Minimizing false positive vulnerability matches
• Validate software naming accuracy
• Document situations where official identifiers are unavailable
• Maintain evidence of vulnerability review activities
• Track newly emerging exploit information

Effective vulnerability mapping strengthens regulatory defensibility during FDA inspections or customer audits.

Step 4: Prioritize Vulnerabilities Using Risk-Based Methodologies

Not every vulnerability creates the same level of patient safety or operational risk.

Manufacturers should apply structured risk prioritization frameworks.

Common Prioritization Factors Include

• CVSS severity scores
• Exploit Prediction Scoring System (EPSS)
• Known exploited vulnerability status
• Device functionality impact
• Clinical safety considerations
• Network exposure
• Likelihood of exploitation
• Availability of compensating controls

If vulnerabilities cannot be immediately remediated, organizations should document:

• Risk justification
• Compensating security controls
• Monitoring plans
• Planned remediation timelines
• Clinical impact assessments

The FDA expects cybersecurity risk decisions to be evidence-based and traceable.

Step 5: Implement Continuous Vulnerability Monitoring

One of the FDA’s clearest expectations is that cybersecurity monitoring must continue throughout the device lifecycle.

Effective Continuous Monitoring Includes

• Automated vulnerability alerts
• Threat intelligence integration
• Periodic risk reassessments
• Software inventory updates
• Post-market cybersecurity reviews
• Incident response coordination

SBOMs should remain current during:

• Software updates
• Security pitches
• New feature releases
• Component replacements
• Maintenance activities
• End-of-life transitions

Static SBOMs rapidly lose regulatory and operational value.

Step 6: Maintain Clear Cybersecurity Documentation

Strong documentation practices are essential for demonstrating cybersecurity governance.

SBOM-Based Documentation Supports

• FDA submissions
• Regulatory inspections
• Internal quality audits
• Hospital cybersecurity reviews
• Healthcare Delivery Organization (HDO) assessments
• Supplier oversight activities

Important Documentation Areas Include

• Vulnerability assessments
• Mitigation rationale
• Patch management decisions
• Residual risk evaluations
• Audit trails
• Threat monitoring records
• Incident response activities

Clear documentation reduces regulatory friction and improves organizational transparency.

Step 7: Establish Secure Patch Management Processes

A mature SBOM program enables more efficient and defensible patch management.

Manufacturers Should Define

• Patch prioritization criteria
• Security update timelines
• Validation testing requirements
• Deployment approval processes
• Communication protocols
• Regulatory impact assessments

Organizations should also evaluate whether updates may trigger:

• FDA reporting obligations
• Post-market submission requirements
• 510(k) considerations
• Risk management updates

Cybersecurity remediation decisions must be balanced:

• Patient safety
• Device functionality
• Regulatory compliance
• Operational continuity

SBOM-Driven Cybersecurity Lifecycle

Why SBOM Governance Matters More Than Ever

Cyberattacks targeting healthcare systems and medical devices continue increasing in both frequency and sophistication.

Threat actors increasingly target:

• Connected medical devices
• Hospital infrastructure
• Clinical software systems
• Remote monitoring platforms
• Network-enabled diagnostic devices

As a result, SBOMs are rapidly becoming:

• A regulatory expectation
• A procurement requirement
• A cybersecurity governance tool
• A patient safety assurance mechanism
• A supply chain transparency framework

Organizations investing early in SBOM governance gain stronger long-term resilience.

Common SBOM Compliance Challenges

Many medical device manufacturers still face operational challenges implementing mature SBOM programs.

Common Issues Include

• Incomplete software inventory
• Poor third-party software visibility
• Inconsistent SBOM formatting
• Limited automation capabilities
• Difficulty tracking legacy components
• Weak vulnerability prioritization processes
• Insufficient post-market monitoring integration
• Limited cross-functional cybersecurity coordination

Addressing these issues requires both technical and regulatory expertise.

Future Trends in Medical Device Cybersecurity Regulation

The regulatory environment for medical device cybersecurity continues evolving rapidly.

Emerging Trends Include

• Greater FDA cybersecurity enforcement
• Increased software supply chain scrutiny
• Expanded post-market cybersecurity obligations
• Stronger vulnerability disclosure expectations
• Enhanced transparency requirements
• Greater harmonization with international cybersecurity standards
• Increased focus on secure-by-design development principles
• More proactive cybersecurity inspection activities

Manufacturers should expect cybersecurity oversight to become increasingly rigorous over the coming years.

Quick Facts

• The FDA expects SBOMs to support ongoing cybersecurity governance
• SBOMs should function as living cybersecurity assets
• Continuous vulnerability monitoring is a key regulatory expectation
• SBOMs support both pre-market and post-market compliance
• Accurate component traceability is essential for vulnerability management
• Patch management decisions should be risk-based and documented
• Cybersecurity is increasingly treated as a patient safety issue
• Strong SBOM governance can reduce regulatory and operational risk

How Maven Regulatory Solutions Supports SBOM Compliance

Our Services

• FDA cybersecurity compliance consulting
• SBOM strategy development
• SBOM validation and governance support
• Vulnerability management framework development
• Medical device cybersecurity documentation
• Secure Product Development Lifecycle (SPDL) consulting
• Post-market cybersecurity strategy
• Threat monitoring process design
• Patch management regulatory assessments
• FDA submission support
• Cybersecurity gap assessments
• Regulatory intelligence monitoring

Why Choose Maven Regulatory Solutions

• Deep expertise in FDA medical device cybersecurity requirements
• Strong understanding of SBOM governance frameworks
• Practical regulatory implementation experience
• Cross-functional cybersecurity and quality expertise
• End-to-end compliance support services
• Experience supporting global medical device manufacturers
• Risk-based cybersecurity strategy development
• Up-to-date regulatory intelligence monitoring

Learn more at Maven Regulatory Solutions.

Need Support with FDA Cybersecurity & SBOM Compliance?

Maven Regulatory Solutions helps medical device manufacturers build practical, scalable, and FDA-aligned SBOM governance programs that support cybersecurity resilience and regulatory readiness.

We Help You With

• FDA cybersecurity compliance
• SBOM lifecycle management
• Vulnerability monitoring frameworks
• Medical device cybersecurity strategy
• Secure software governance
• Post-market cybersecurity programs
• Patch management planning
• Regulatory documentation support
• Cybersecurity risk assessments
• Software supply chain visibility

Partner With Maven Regulatory Solutions To

• Strengthen FDA cybersecurity compliance
• Improve vulnerability management
• Reduce regulatory audit risk
• Enhance patient safety protection
• Build resilient cybersecurity governance
• Support long-term market access

Contact Maven Regulatory Solutions today to strengthen your medical device cybersecurity and SBOM compliance strategy.

Conclusion

SBOM management is no longer simply a regulatory submission exercise.

For modern medical devices, SBOM has become the foundation of continuous cybersecurity governance, vulnerability management, and post-market risk control.

Manufacturers that establish structured, risk-based SBOM management programs will be better positioned to:

• Meet FDA cybersecurity expectations
• Improve vulnerability response capabilities
• Strengthening software supply chain transparency
• Reduce patient safety risks
• Support post-market cybersecurity compliance
• Maintain long-term regulatory defensibility

As cyber threats continue evolving, proactive SBOM governance will become increasingly essential for medical device manufacturers operating in highly regulated global markets.

Organizations that invest early in scalable cybersecurity governance frameworks will gain stronger operational resilience and competitive regulatory advantage.

Maven Regulatory Solutions stands ready to support your organization through the evolving medical device cybersecurity landscape.

Frequently Asked Questions 

1. Is SBOM mandatory for FDA medical device submissions?

For certain software-enabled and cyber-connected medical devices, yes. FDA cybersecurity guidance increasingly expects SBOM inclusion.

2. How often should an SBOM be updated?

SBOMs should be updated whenever software components change, vulnerabilities emerge, or significant cybersecurity updates occur.

3. Does SBOM management apply to post-market activities?

Yes. The FDA explicitly expects ongoing post-market cybersecurity monitoring and vulnerability management.

4. What happens if a vulnerability cannot be patched immediately?

Manufacturers should document risk justification, compensating controls, monitoring activities, and planned remediation strategies.

5. Why are SBOMs important for patient safety?

Cybersecurity vulnerabilities may affect device functionality, availability, integrity, and ultimately patient safety.

6. Can SBOM governance reduce regulatory inspection risk?

Yes. Well-managed SBOM systems demonstrate proactive cybersecurity governance and regulatory maturity.

7. How can Maven Regulatory Solutions help?

Maven supports FDA cybersecurity compliance, SBOM governance, vulnerability management, regulatory documentation, and post-market cybersecurity strategy development.